UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell ...

The company finished September with $1.9 billion in cash. A big cash pile gives CRISPR Therapeutics a long runway to ramp up ...

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...

CRISPR gene editing is widely regarded as one of the most important leaps in biomedical and agricultural research, with ...

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

The Research Institute of the McGill University Health Centre is at the forefront of clinical trials in precision cancer ...

Penny stocks are shares of smaller or newer companies, often in their early stages of development. These companies, however, ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

CRISPR-based gene-editing tools are being developed to correct specific defective sections of the genome to cure inherited genetic diseases, with some applications already in clinical trials. However, ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...